300 related articles for article (PubMed ID: 30040306)
1. [The denosumab dilemma: to be stopped after 5 years or to be continued in patients with osteoporosis?].
Wolffenbuttel BHR; Abma EM; Appelman-Dijkstra NM
Ned Tijdschr Geneeskd; 2018 May; 162():. PubMed ID: 30040306
[TBL] [Abstract][Full Text] [Related]
2. [How to manage the rebound effect at denosumab discontinuation and avoid multiple vertebral fractures?].
Gonzalez Rodriguez E; Lamy O; Aubry-Rozier B; Stoll D; Uebelhart B
Rev Med Suisse; 2019 Apr; 15(647):831-835. PubMed ID: 30994986
[TBL] [Abstract][Full Text] [Related]
3. Stopping Denosumab.
Lamy O; Stoll D; Aubry-Rozier B; Rodriguez EG
Curr Osteoporos Rep; 2019 Feb; 17(1):8-15. PubMed ID: 30659428
[TBL] [Abstract][Full Text] [Related]
4. Dilemma of denosumab therapy: rebound fractures with denosumab cessation or dose delay.
Herath M; Wong P; Milat F
Intern Med J; 2021 Feb; 51(2):297-298. PubMed ID: 33631850
[No Abstract] [Full Text] [Related]
5. Rebound-associated vertebral fractures after stopping denosumab: Report of four cases.
Dupont J; Laurent MR; Dedeyne L; Luyten FP; Gielen E; Dejaeger M
Joint Bone Spine; 2020 Mar; 87(2):171-173. PubMed ID: 31369866
[No Abstract] [Full Text] [Related]
6. Drug holidays in women treated for postmenopausal osteoporosis.
McClung MR
Menopause; 2018 Oct; 25(10):1152-1154. PubMed ID: 30044265
[TBL] [Abstract][Full Text] [Related]
7. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
8. Second rebound-associated vertebral fractures after denosumab discontinuation.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Arch Osteoporos; 2020 Jan; 15(1):7. PubMed ID: 31898803
[TBL] [Abstract][Full Text] [Related]
9. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C
Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455
[TBL] [Abstract][Full Text] [Related]
11. Multiple Rebound-Associated Vertebral Fractures after Denosumab Discontinuation: Is Prompt Antiresorptive Therapy Always Recommended,Even When the Risk of Fracture Seems Low? A Case Report.
Osella G; Puglisi S; Alì A; Reimondo G; Terzolo M
Endocr Metab Immune Disord Drug Targets; 2021; 21(12):2303-2306. PubMed ID: 34238202
[TBL] [Abstract][Full Text] [Related]
12. Vertebral Fractures Following Denosumab Discontinuation in Patients with Prolonged Exposure to Bisphosphonates.
Tripto-Shkolnik L; Rouach V; Marcus Y; Rotman-Pikielny P; Benbassat C; Vered I
Calcif Tissue Int; 2018 Jul; 103(1):44-49. PubMed ID: 29396698
[TBL] [Abstract][Full Text] [Related]
13. Drug-Related Adverse Events of Osteoporosis Therapy.
Khan M; Cheung AM; Khan AA
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):181-192. PubMed ID: 28131131
[TBL] [Abstract][Full Text] [Related]
14. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
15. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
16. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
Ramchand SK; Chiang CY; Zebaze RM; Seeman E
Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
[TBL] [Abstract][Full Text] [Related]
17. Update on osteoporosis treatment.
Nogués X; Martinez-Laguna D
Med Clin (Barc); 2018 Jun; 150(12):479-486. PubMed ID: 29179892
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
Diédhiou D; Cuny T; Sarr A; Norou Diop S; Klein M; Weryha G
Ann Endocrinol (Paris); 2015 Dec; 76(6):650-7. PubMed ID: 26639186
[TBL] [Abstract][Full Text] [Related]
19. Denosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis.
Zeytinoglu M; Naaman SC; Dickens LT
Endocrinol Metab Clin North Am; 2021 Jun; 50(2):205-222. PubMed ID: 34023039
[TBL] [Abstract][Full Text] [Related]
20. Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women.
Ha J; Kim J; Jeong C; Lim Y; Kim MK; Kwon HS; Song KH; Kang MI; Baek KH
Osteoporos Int; 2022 Jul; 33(7):1591-1599. PubMed ID: 35376989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]